RAPT Therapeutics (NASDAQ:RAPT) Given Neutral Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research note issued to investors on Monday,Benzinga reports.

Other analysts have also issued reports about the company. Wells Fargo & Company reduced their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Stifel Nicolaus restated a “hold” rating and set a $2.00 price objective (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. UBS Group dropped their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research report on Monday, September 9th. Finally, JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, RAPT Therapeutics presently has an average rating of “Hold” and an average price target of $9.50.

RAPT Therapeutics Stock Performance

RAPT opened at $1.12 on Monday. The firm has a market cap of $39.16 million, a P/E ratio of -0.40 and a beta of 0.33. RAPT Therapeutics has a 52-week low of $1.00 and a 52-week high of $27.35. The business’s fifty day moving average is $1.83 and its 200-day moving average is $2.65.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. On average, research analysts predict that RAPT Therapeutics will post -2.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in RAPT Therapeutics in the first quarter valued at about $97,000. Readystate Asset Management LP acquired a new stake in shares of RAPT Therapeutics in the third quarter valued at about $36,000. XTX Topco Ltd acquired a new stake in shares of RAPT Therapeutics in the second quarter valued at about $108,000. Barclays PLC increased its stake in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its stake in shares of RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after buying an additional 3,824 shares during the period. 99.09% of the stock is currently owned by institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.